http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201301266-A8
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 |
| filingDate | 2013-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201301266-A8 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION CONTAINING NALBUFIN HYDROCHLORIDE, ITS APPLICATION FOR THE TREATMENT OF MEDICAL SYNDROME OF MEDIUM AND HIGH INTENSITY AND METHOD OF OBTAINING THE PHARMACEUTICAL COMPOSITION |
| abstract | The invention relates to the field of medicine and the pharmaceutical industry, specifically to the creation, production and use of a medicament for the treatment (relief) of moderate and high intensity pain in various fields of medicine, in particular in oncology. The objective of this invention is to create new pharmaceutical compositions in the form of rectal suppositories containing nalbuphine or its salt on different suppository bases, intended for the treatment (relief) of moderate to high intensity pain attacks with an effective and prolonged analgesic effect in the absence of a laxative effect, and also in the development of methods for producing these compositions. To solve this problem, the use of nalbuphine salt in the form of suppositories on a hydrophilic emulsion base for the treatment of moderate and high intensity pain syndrome is proposed. The pharmaceutical composition for the treatment of moderate to high intensity pain in the form of suppositories includes nalbuphine hydrochloride and a suppository base as the active ingredient. As a suppository base, the composition contains a hydrophilic emulsion base, including formers, poloxamer, filler, emulsifier, propylene glycol and polyethylene oxide 400 as a solvent. Moreover, the composition preferably comprises polyethylene oxide 4000 and polyethylene oxide 1500 as forming agents, and the poloxamer is poloxamer 188. Moreover, the composition preferably contains solid fat as a filler. In addition, as an emulsifier |
| priorityDate | 2012-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.